NGL Fine-Chem Share Price Today (NGLFINE)
TODAY IN ONE LINE
Closed at ₹3,179.3 (+0.58%); delivery 36.7%. Market opens 9:15 IST. · as of 11:35 IST
With a market cap of ₹1,963.01 Cr., it trades at a P/E of 41.59. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
NGL Fine-Chem flags
Key strengths and potential risks.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 1539.8% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 57.1% and Profit up 2398.0%
- ●High Capital EfficiencyROCE of 17.0% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 15.7%
- ●High Promoter HoldingPromoters hold 72.7% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified.
What changed recently?
Recent events, corporate actions, and announcements.
NGL Fine-Chem Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for NGL Fine-Chem Limited, framed against the sector median so the premium or discount is obvious at a glance.
NGL Fine-Chem Limited trades at a P/E of 41.59× and P/B of 6.08×.
Valuation
Profitability
Growth
Financial Health
NGL Fine-Chem Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for NGL Fine-Chem Limited — derived from the live tape, not yesterday's close.
NGL Fine-Chem Limited last traded at ₹3,179.3 with an intraday range of ₹3,108.1–₹3,198 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹3179.30| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 3395.30 | +216.00 | +6.79% |
| R3 | 3305.40 | +126.10 | +3.97% |
| R2 | 3251.70 | +72.40 | +2.28% |
| R1 | 3215.50 | +36.20 | +1.14% |
| PIVOT | 3161.80 | -17.50 | -0.55% |
| CURRENT | 3179.30 | — | — |
| S1 | 3125.60 | -53.70 | -1.69% |
| S2 | 3071.90 | -107.40 | -3.38% |
| S3 | 3035.70 | -143.60 | -4.52% |
| S4 | 2945.80 | -233.50 | -7.34% |
NGLFINE is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹3108.1–₹3198
Trading Inside opening range
NGL Fine-Chem Limited financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for NGL Fine-Chem Limited, switchable between annual and quarterly views, consolidated or standalone.
NGL Fine-Chem Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1,963.01 Cr. and reported EPS of ₹78.04.
| Period | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | 152 | 258 | 318 | 278 | 339 | 368 | 501 |
| Other Income | 3 | 8 | 11 | 6 | 14 | 9 | 15 |
| Total Income | 155 | 266 | 328 | 284 | 353 | 377 | 516 |
| Cost of Goods Sold (COGS) | 64 | 102 | 147 | 140 | 159 | 182 | 239 |
| Gross Profit | 87 | 156 | 171 | 138 | 180 | 186 | 261 |
| +Operating Expenses | 68 | 76 | 103 | 103 | 127 | 152 | 189 |
| EBITDA | 19 | 80 | 68 | 34 | 53 | 34 | 73 |
| +Non-Operating Expenses | 10 | 10 | 12 | 12 | 13 | 15 | 24 |
| Profit Before Tax (PBT) | 12 | 78 | 67 | 27 | 54 | 28 | 63 |
| +Tax Expense | 4 | 21 | 17 | 7 | 13 | 7 | 15 |
| Total Profit for Period | 8 | 57 | 50 | 20 | 41 | 21 | 48 |
| Net Profit (Owner's PAT) | 8 | 57 | 50 | 20 | 41 | 21 | 48 |
| Earnings Per Share (EPS) | 13.49 | 91.81 | 80.77 | 33.18 | 66.88 | 34.19 | 77.90 |
| Diluted Shares Outstanding (Nos.) | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| +Additional Disclosures | 207 | 291 | 409 | 396 | 457 | 531 | 692 |
| Sales Growth % | — | 70.07 | 23.08 | -12.42 | 21.79 | 8.73 | 36.03 |
| YoY Sales Growth % | — | 70.07 | 23.08 | -12.42 | 21.79 | 8.73 | 36.03 |
| Material Cost % | 46 | 39 | 53 | 42 | 50 | 50 | 49 |
| Employee Cost % | 16 | 11 | 11 | 13 | 13 | 15 | 13 |
| Other Cost % | 29 | 19 | 21 | 24 | 24 | 26 | 25 |
| OPM % | 13 | 31 | 21 | 12 | 16 | 9 | 15 |
| Tax % | 31 | 27 | 25 | 25 | 24 | 24 | 24 |
| Profit Growth % | — | 580.47 | -12.03 | -58.92 | 101.58 | -48.87 | 127.83 |
| Gross Margin % | 57.57 | 60.33 | 53.70 | 49.54 | 53.15 | 50.47 | 52.19 |
| EBITDA Margin % | 12.78 | 30.91 | 21.37 | 12.34 | 15.73 | 9.20 | 14.51 |
| Interest Coverage Ratio | 5.00 | 38.81 | 36.81 | 19.24 | 31.11 | 9.18 | 11.89 |
| Ebit | 11 | 71 | 57 | 23 | 42 | 21 | 53 |
NGL Fine-Chem segment analysis: revenue and profit mix.
Disclosed business segments at NGL Fine-Chem with their share of revenue and profit, switchable between consolidated and standalone reporting.
NGL Fine-Chem discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for NGL Fine-Chem Limited.
Our AI distills the core fundamental drivers supporting NGL Fine-Chem Limited, the risks that threaten it, and the exact valuation or growth triggers that should make you re-evaluate.
NGL Fine-Chem Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
TTM revenue growth 57.2% significantly outpaces pharmaceutical sector peers at 7-11% annually.
Promoter holding 72.74% demonstrates strong founder commitment and long-term strategic alignment.
Debt-to-equity ratio 0.0033 remains exceptionally conservative, providing substantial financial flexibility.
Operating margin 10.60% TTM maintains profitability despite competitive pharmaceutical landscape pressures.
Positive operating cash flow ₹34.73 Cr (FY2026) supports dividend payments and capex funding.
Key Risks.
Latest quarterly EPS grew 1,536.6% YoY, signaling extreme earnings volatility and unpredictability.
ROCE 17.00% substantially lags peer median ~22%, indicating weak capital deployment efficiency.
P/E ratio 38.32x trades at premium versus peer median ~20x, suggesting overvaluation concerns.
Zero institutional ownership and FII holdings 0.00% raise liquidity and market confidence issues.
Free cash flow -₹29.84 Cr (FY2026) negative despite positive operating cash flow signals capex strain.
Flip Conditions.
Trim if P/E re-rates above 54. The valuation cushion thins from there.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Exit if ROE slips below 11%. The operating engine is no longer compounding capital efficiently.
Income thesis breaks if the dividend is cut or yield falls below 0.03%.
NGL Fine-Chem Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — NGL Fine-Chem Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
NGL Fine-Chem Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for NGL Fine-Chem Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
NGL Fine-Chem Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for NGL Fine-Chem Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in NGL Fine-Chem Limited stood at 36.7% of traded volume, against a 20-day average of 45.6%.
NGL Fine-Chem announcements: results, concalls, ratings, M&A.
Filings NGL Fine-Chem sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
NGL Fine-Chem files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 51 documents below.
Trading Window
NGL Fine-Chem Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations,…
Disclosure under SEBI Takeover Regulations
Rajesh Lawande has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial…
Copy of Newspaper Publication
NGL Fine-Chem Limited has informed the Exchange about Copy of Newspaper Publication
Certificate under SEBI (Depositories and Participants) Regulations, 2018
NGL Fine-Chem Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Credit Rating- Revision
NGL Fine-Chem Limited has informed the Exchange about Credit Rating- Revision
Investor decks & rating reports.
NGL Fine-Chem dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue NGL Fine-Chem has declared, sequenced by announce and record date.
NGL Fine-Chem corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About NGL Fine-Chem Limited: business, sector, key facts.
What NGL Fine-Chem Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
NGL Fine-Chem Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: NGLFINE, BSE: 524774.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Other overvalued NSE stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about NGL Fine-Chem Limited (NGLFINE).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of NGL Fine-Chem Limited (NGLFINE)?
The current share price of NGL Fine-Chem Limited (NGLFINE) is ₹3,179.3. Today, the stock has gained by ₹18.40 (0.58%), trading in a range of ₹3,108.1 to ₹3,198. The stock opened at ₹3,198 with a trading volume of 1,405 shares.
02Is NGL Fine-Chem Limited stock a good investment for long-term?
NGL Fine-Chem Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,963.01 crores, P/E ratio of 41.59, ROE of 15.70%, and ROCE of 17.00%. The dividend yield stands at 0.05%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of NGL Fine-Chem Limited stock?
The 52-week high price of NGL Fine-Chem Limited (NGLFINE) is ₹3,329, while the 52-week low is ₹1,175.5. Currently trading at ₹3,179.3, the stock is 93.0% away from its 52-week low and 4.5% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy NGL Fine-Chem Limited stock at the current price?
Whether to buy NGL Fine-Chem Limited stock at ₹3,179.3 depends on multiple factors. The stock is currently trading with a P/E ratio of 41.59 and P/B ratio of 6.08. Today's performance shows a gain of 0.58%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of NGL Fine-Chem Limited and when is the next dividend?
NGL Fine-Chem Limited offers a dividend yield of 0.05%, which means for every ₹100 invested at the current price of ₹3,179.3, you can expect to receive approximately ₹0.05 annually as dividends. The face value of the stock is ₹5.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of NGL Fine-Chem Limited?
NGL Fine-Chem Limited's key financial metrics include: P/E Ratio: 41.59, P/B Ratio: 6.08, ROE: 15.70%, ROCE: 17.00%, Dividend Yield: 0.05%, EPS: ₹78.04, Book Value: ₹532.95, and Debt-to-Equity: 0.00. The company's market cap stands at ₹1,963.01 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is NGL Fine-Chem Limited stock performing today in the market?
NGL Fine-Chem Limited stock opened at ₹3,198 and is currently trading at ₹3,179.3, showing a gain of ₹18.40 (0.58%). The intraday high is ₹3,198 and low is ₹3,108.1. The trading volume stands at 1,405 shares, indicating moderate market participation today.
08What is the P/E ratio of NGL Fine-Chem Limited and what does it indicate?
NGL Fine-Chem Limited has a Price-to-Earnings (P/E) ratio of 41.59, which means investors are willing to pay ₹41.59 for every ₹1 of earnings. With an EPS of ₹78.04, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about NGL Fine-Chem Limited (NGLFINE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.